Medical devices will lose share in terms of revenues in the total US anti-migraine market by 2022

NEW YORK - April 21, 2018 - PRLog -- Anti-migraine medical devices will grab 5% market share in the United Kingdom and  3% in Germany in revenues in 2022

Whilst medical devices will gain two percentage points versus therapeutic drugs from 2018 to 2022 in terms of market share revenues for the total UK and German anti-migraine markets, CR Life Sc predicts that medical devices will lose two percentage points to grab only 7% of the total market to treat migraine in the United States.

Despite the appearance of new medical devices, therapeutic drugs will still lead this market

93% of revenues are expected to be generated by therapeutic drugs in 2022 in the United States. Anti-CGRP monoclonal antibodies and gepants together with new preventive drugs will help to drive the anti-migraine therapeutic drugs market.

CR Life Sc estimates that neurostimulators and intraoral devices will have growth rates above 16% in revenues by 2022.

CR Life Sc is a Strategic Market Consultancy focused on pharmaceuticals, diagnostics and medical devices markets.

For more information follow this link (https://crlifesc.com/anti-migraine/).

www.crlifesc.com